Search

News Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?

As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS JEP was released. Let's take a look at what changes it has brought compared to the previous version in the treatment of metastatic non-small cell lung cancer (NSCLC) with a driver mutation in the ALK gene.

Source: Genetic Profile and Treatment of NSCLC 27. 12. 2021

News Current Data of Tofacitinib in the Treatment of IBD: What Improvements in Endoscopic and Histologic Outcomes Can Be Achieved?

The oral Janus kinase inhibitor (JAKi) tofacitinib is currently approved for the treatment of moderately to severely active ulcerative colitis (UC). Its efficacy and safety in this indication have previously been investigated in randomized placebo-controlled trials. However, the study discussed below examined the drug's impact on the endoscopic and histological progression of the disease and fecal calprotectin levels.

Source: Intestinal Inflammations 20. 9. 2023

News COMMENTARY FROM PRACTICE: On Some Aspects of Care for Patients with Parkinson's Disease

What issues do we still encounter in the diagnosis and treatment of Parkinson's disease even today, despite medical advancements? How to fine-tune the management of care for these patients, facilitate their path to effective therapy, and improve their quality of life using current possibilities? What can their treating neurologist do for them, when is it necessary to consult a specialized center without delay, and how to mitigate the stigmatization associated with this disease? These aspects are also considered in the following commentary from practice.

Source: Parkinson's Disease 15. 5. 2023

News Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene

PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt −⁠ wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.

Source: Colorectal Cancer 14. 10. 2023

News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab

Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.

Source: Quality Life Even with Hemophilia 28. 7. 2020

News Brentuximab vedotin in combination with lenalidomide and rituximab in R/R DLBCL –⁠ results from the open part of the ECHELON-3 study

The aim of the open run-in phase of the randomized placebo-controlled phase III ECHELON-3 study, the results of which were presented at the ASCO and EHA 2022 congresses, was to evaluate the efficacy and safety of the brentuximab vedotin/lenalidomide/rituximab (BV-len-R) triplet in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Source: Hematologic Malignancies 10. 8. 2022

News Bilastine as a reliable helper in the treatment of allergic rhinoconjunctivitis and urticaria even in younger children

Until recently, bilastine was indicated for the treatment of allergic rhinoconjunctivitis and urticaria only in patients over 12 years of age. However, current findings from valid studies demonstrate the safety and efficacy of its use even in younger individuals.

Source: Allergic Reactions 21. 7. 2021

News International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders

At the end of December 2020, international guidelines for COVID-19 vaccination in people with bleeding disorders were published on the World Federation of Hemophilia (WFH) website. We present a basic summary of 13 points of this consensus. The original English version is available via the web link cited at the end of the article.

Source: Hemophilia 8. 2. 2021

News Early Detection of Erectile Dysfunction in Men with Type 2 Diabetes

A retrospective study published last year identified predictors of erectile dysfunction in men with type 2 diabetes. The authors recommend screening patients with elevated uric acid levels, diabetes duration ≥ 49 months, and diabetic retinopathy.

Source: Diabetes 18. 7. 2022

News Study PLATON: romiplostim in patients with ITP in real clinical practice

Recently, the results of the PLATON study with romiplostim, which was conducted in Central and Eastern European countries including the Czech Republic, were published. It was an observational non-interventional cohort study from real practice, and romiplostim was used within its approved indication.

Source: Immune Thrombocytopenia 8. 6. 2020

News Does gliflozin treatment for heart failure have greater benefits in diabetics?

Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic market by several molecules including empagliflozin. The EMPEROR-Reduced study monitored the impact of empagliflozin administration in individuals with heart failure with reduced ejection fraction (HFrEF) and compared the results in patients with and without diabetes.

Source: Heart Failure 3. 3. 2022

News Retention –⁠ An Overlooked Parameter of Incontinence Products

In the Czech Republic and other European countries, the main criterion when choosing an incontinence product, apart from its size, is primarily absorption. This defines the amount of fluid the product can hold in its absorbent core, but it does not tell anything about its retention capability. What is retention and why is it important to know?

Source: Incontinence 9. 4. 2021

News Safety and Efficacy of Different Antithrombotic Regimens in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention

Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI) require antithrombotic therapy for the prevention of atherothrombosis, stent thrombosis, and cerebrovascular stroke (CVS). The meta-analysis presented below attempted to clarify which antithrombotic regimen is most suitable in terms of safety and efficacy for these patients.

Source: Anticoagulant Treatment 13. 3. 2020

Články časopisu Assessment of health status for the purposes of benefi ts and social security services for people with lung cancer and the economic impact of this disease on social security in the Czech Republic

Author of the article: M. Bosák, M. Másilková, V. Kahoun Source: Klinická onkologie | 2/2021 16. 4. 2021

News Extended Thromboprophylaxis with Enoxaparin After Bariatric Surgery

A recent retrospective study involving 312 patients after bariatric surgery indicated that extended thromboprophylaxis might be an appropriate approach for preventing postoperative venous thromboembolism in these patients. In this study, the authors administered enoxaparin at a dose of 40 mg subcutaneously twice daily for 10-14 days in the majority of operated patients without an increased risk of bleeding.

Source: Thromboprophylaxis 29. 4. 2021